Navigation Links
Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
Date:9/24/2008

FDA Expert on Pharmacogenomics Offers a Prescription for Progress

WATERBURY, Conn., Sept. 24 /PRNewswire/ -- The Connecticut State Medical Society is joining with Genomas(R), a biomedical company advancing DNA-guided medicine and personalized healthcare, to co-sponsor a symposium -- DNA-Guided Medicine and the Path to Personalized Health Care -- being held today at the Society's annual meeting. Hartford Hospital is providing continuing medical education credits for physicians attending the meeting.

Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, will discuss FDA Initiatives in Personalized Medicine: Advancing Individualized Drug Therapy.

Dr Lesko commented: "The U.S. Department of Health and Human Services and the FDA have prioritized personalized medicine as one of their mission goals for public health. I am glad to participate in this event with the Connecticut Medical Society, Hartford Hospital and Genomas to bring these initiatives to physicians who are in an important position to implement them in their clinical practice. Connecticut is poised to become one of the national leaders in adoption of personalized medicine, and I am thrilled to join ranks with these local efforts as exemplary to improving the healthcare system as a whole."

Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, will speak about Progress Towards DNA-Guided Medicine in Clinical Practice: Case Studies in Cardiology and Psychiatry. Examples in these two therapeutic areas include statins and atypical antipsychotics.

Dr. Ruano commented: "We are privileged to partner with the Connecticut State Medical Society to convene the physicians in our state for this forum. The presence of the FDA is an indication of the national impact of the programs in DNA-Guided Medicine that Genomas has spearheaded in Connecticut with Hartford Hospital and the Hospital of Central Connecticut. Together, we are bringing personalized healthcare to our patients today, and setting the pathway to utilization of DNA-Guided Medicine as the standard of care in cardiovascular and psychiatric clinical practice."

ABOUT GENOMAS

Genomas Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with the unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information, please visit http://www.genomas.net

ABOUT PHYZIOTYPE CLINICAL MANAGEMENT SYSTEMS

PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a biomathematical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. To date, Genomas has secured $3.1 million from NIH Small Business Innovation Research (SBIR) for PhyzioType System product development.


'/>"/>
SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Connecticut Technology Council to Recognize Fast Growing Technology Companies
2. Connecticut BioBus Travels to State Capitol on April 24 for Tours and Experiments with Visiting Students
3. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
4. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
5. NC State engineers discover nanoparticles can break on through
6. Department of Justice Provides States With Funding for Testing in Postconviction Cases
7. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
8. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
9. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
10. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
11. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... 2017 , ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, ... . GGI's mission is to advance global health and highlight the greater good of ... of each clinical trial volunteer. The vision of GGI is to serve as a ...
Breaking Biology Technology:
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):